38,753 Shares in CRISPR Therapeutics AG $CRSP Acquired by Wealth Enhancement Trust Services Inc.

Wealth Enhancement Trust Services Inc. bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 38,753 shares of the company’s stock, valued at approximately $2,032,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of CRISPR Therapeutics by 5.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after purchasing an additional 180 shares during the last quarter. Cerity Partners LLC increased its position in shares of CRISPR Therapeutics by 3.0% during the 2nd quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock worth $318,000 after purchasing an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp raised its holdings in CRISPR Therapeutics by 3.0% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock valued at $339,000 after buying an additional 200 shares during the period. Optiver Holding B.V. raised its holdings in CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after buying an additional 210 shares during the period. Finally, US Bancorp DE lifted its position in CRISPR Therapeutics by 4.5% in the third quarter. US Bancorp DE now owns 5,777 shares of the company’s stock valued at $374,000 after buying an additional 249 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Truist Financial raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Piper Sandler reissued an “overweight” rating and issued a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Chardan Capital upped their price objective on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a report on Saturday, February 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Finally, Needham & Company LLC lifted their target price on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $64.53.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 60,000 shares of the stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the sale, the chief executive officer owned 134,201 shares of the company’s stock, valued at $8,082,926.23. This trade represents a 30.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Naimish Patel sold 3,150 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $48.26, for a total value of $152,019.00. Following the completion of the sale, the insider directly owned 13,143 shares in the company, valued at $634,281.18. This represents a 19.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 141,828 shares of company stock worth $7,744,397. Company insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Stock Up 4.1%

Shares of CRSP opened at $57.99 on Friday. The company has a market cap of $5.57 billion, a P/E ratio of -8.89 and a beta of 1.80. CRISPR Therapeutics AG has a fifty-two week low of $33.03 and a fifty-two week high of $78.48. The firm’s 50 day moving average price is $52.10 and its 200 day moving average price is $55.97.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Friday, February 13th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. During the same period in the prior year, the business earned ($1.01) EPS. The business’s quarterly revenue was down 97.8% on a year-over-year basis. Research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.